Insulin detemir reduces the risk of hypoglycaemia at all levels of HbA1c compared to NPH insulin in the context of basal-bolus therapy for type 1 diabetes

被引：0
|
作者：
Jones, DR
Kim, H
Heller, S
Clauson, P
机构：
[1] Royal Surrey Cty Hosp, Dept Endocrinol & Diabet, Guildford, Surrey, England
[2] Univ Sheffield, Sheffield, S Yorkshire, England
[3] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
来源：
DIABETOLOGIA | 2005年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
243
引用
收藏
页码：A92 / A93
页数：2
相关论文
共 50 条
  • [41] Transferring the basal component of basal-bolus therapy from NPH insulin to insulin detemir improves glycemic control and reduces hypoglycemia and bodyweight in type 1 and 2 patients:: 6-month results from PREDICTIVE™
    Sreenan, Seamus
    Aczel, Stefan
    Merilainen, Markus
    Virkamaki, Antti
    DIABETES, 2007, 56 : A557 - A557
  • [42] Insulin detemir incurs a lower risk of hypoglycaemia than NPH insulin for any level of HbA1c when added to oral agents in a treat-to-target protocol for patients with type 2 diabetes
    Kolendorf, K
    Kim, H
    Clauson, P
    DIABETOLOGIA, 2005, 48 : A302 - A303
  • [43] Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial
    Tinahones, F. J.
    Gomez-Huelgas, R.
    Garcia-Alegria, J.
    Tapia-Guerrero, M.
    Martos-Perez, F.
    DIABETOLOGIA, 2011, 54 : S273 - S273
  • [44] Insulin analogues (insulin detemir and insulin aspart) in comparison with traditional human insulin (NPH-insulin and short-acting human insulin) in basal bolus therapy of type 1 diabetes mellitus
    Khermansen, K.
    Fonten, P.
    Kukolyya, K. K.
    Peterkova, V. A.
    Leyt, G.
    Gall, M.
    DIABETES MELLITUS, 2006, 9 (01): : 18 - 26
  • [45] FEAR OF HYPOGLYCAEMIA BETWEEN PEOPLE WITH TYPE 1 DIABETES ON INSULIN PUMP VERSUS BASAL BOLUS INSULIN THERAPY
    Papazafiropoulou, A.
    Kourtidou, F.
    Tentolouris, N.
    Antonopoulos, S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A167 - A168
  • [46] Impact of Bolus/Basal Insulin Ratio on HbA1c and Lipid Profile in Adult Patients with Type 1 Diabetes Mellitus
    Calapkulu, Murat
    Sencar, Muhammed Erkam
    Unsal, Ilknur Ozturk
    Sakiz, Davut
    Ozbek, Mustafa
    Cakal, Erman
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2023, 33 (09): : 990 - 994
  • [47] Contribution of fasting and postprandial plasma glucose to HbA1c in people with type 2 diabetes on basal-bolus insulin: a meta-analysis of insulin lispro clinical trials
    Liao, B.
    Chen, Y.
    Chigutsa, F.
    de Oliveira, C. Piras
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S332 - S332
  • [48] A comparison of the cost-effectiveness of basal-bolus therapy of Type 1 diabetes using insulin detemir plus insulin aspart versus human insulin-based regimens
    Palmer, AJ
    Roze, S
    Valentine, WJ
    Smith, IC
    Wittrup-Jensen, K
    DIABETOLOGIA, 2004, 47 : A344 - A344
  • [49] Addition of alogliptin to insulin therapy reduces HbA1c without increasing weight gain or hypoglycaemia in patients with type 2 diabetes
    Rendell, M.
    Rosenstock, J.
    Gross, J.
    Fleck, P.
    Wilson, C.
    Mekki, Q.
    DIABETOLOGIA, 2008, 51 : S37 - S38
  • [50] The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target<7.0%
    Liebl, A.
    Prager, R.
    Kaiser, M.
    Binz, K.
    Gailwitz, B.
    DIABETOLOGIA, 2006, 49 : 610 - 611
12345